CN103288978A - 岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用 - Google Patents
岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用 Download PDFInfo
- Publication number
- CN103288978A CN103288978A CN2013102287285A CN201310228728A CN103288978A CN 103288978 A CN103288978 A CN 103288978A CN 2013102287285 A CN2013102287285 A CN 2013102287285A CN 201310228728 A CN201310228728 A CN 201310228728A CN 103288978 A CN103288978 A CN 103288978A
- Authority
- CN
- China
- Prior art keywords
- fucoidan
- preparation
- alpha
- antidiabetic
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 title claims abstract description 15
- 230000003178 anti-diabetic effect Effects 0.000 title claims abstract description 15
- 239000003472 antidiabetic agent Substances 0.000 title claims abstract description 13
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title abstract description 7
- 229910021653 sulphate ion Inorganic materials 0.000 title abstract 6
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 13
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 7
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims abstract description 7
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 238000001556 precipitation Methods 0.000 claims abstract description 7
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 6
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 claims abstract description 5
- 239000001110 calcium chloride Substances 0.000 claims abstract description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 5
- 238000003809 water extraction Methods 0.000 claims abstract description 3
- 229920000855 Fucoidan Polymers 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 14
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 102000001554 Hemoglobins Human genes 0.000 claims description 10
- 108010054147 Hemoglobins Proteins 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 229960003487 xylose Drugs 0.000 claims description 9
- 230000000291 postprandial effect Effects 0.000 claims description 8
- 241000227647 Fucus vesiculosus Species 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims description 2
- 239000003518 caustics Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000006384 oligomerization reaction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 230000008901 benefit Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 abstract 1
- 241000199919 Phaeophyceae Species 0.000 abstract 1
- 150000002772 monosaccharides Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 20
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 12
- 229960002632 acarbose Drugs 0.000 description 10
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000195480 Fucus Species 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000196251 Ulva arasakii Species 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000008267 fucoses Chemical class 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- -1 polysaccharide sulfate Chemical class 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310228728.5A CN103288978B (zh) | 2013-06-08 | 2013-06-08 | 岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310228728.5A CN103288978B (zh) | 2013-06-08 | 2013-06-08 | 岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103288978A true CN103288978A (zh) | 2013-09-11 |
CN103288978B CN103288978B (zh) | 2015-10-28 |
Family
ID=49090552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310228728.5A Active CN103288978B (zh) | 2013-06-08 | 2013-06-08 | 岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103288978B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103554293A (zh) * | 2013-11-18 | 2014-02-05 | 集美大学 | 一种活性低分子量岩藻聚糖的制备方法及其用途 |
CN104173231A (zh) * | 2014-08-04 | 2014-12-03 | 法国微拉芙生命科学研究院亚洲研发中心有限公司 | 墨角藻提取物的提取方法及其在抗衰老化妆品中的应用 |
CN104586878A (zh) * | 2015-01-14 | 2015-05-06 | 青岛海洋生物医药研究院股份有限公司 | 岩藻聚糖硫酸酯及低分子量岩藻聚糖硫酸酯在制备抗代谢综合症的药物和保健品中的应用 |
CN104710539A (zh) * | 2013-12-17 | 2015-06-17 | 深圳海王药业有限公司 | 岩藻聚糖硫酸酯及其制备方法 |
CN106749733A (zh) * | 2016-12-21 | 2017-05-31 | 盐城工学院 | 一种泡叶藻硫酸酯化多糖及其制备方法、应用 |
CN110437288A (zh) * | 2019-09-02 | 2019-11-12 | 中国海洋大学 | 一种新型海参岩藻多糖及其制备方法和应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040105523A (ko) * | 2003-06-07 | 2004-12-16 | 박응렬 | 갈조류로 부터 생리활성물질 연속추출 및 기능성 식품제조 |
CN1560086A (zh) * | 2004-03-12 | 2005-01-05 | 中国海洋大学 | 一种高硫酸根含量岩藻聚糖硫酸酯的制备方法 |
JP2006233099A (ja) * | 2005-02-25 | 2006-09-07 | Univ Of Ryukyus | 褐藻類盤状体由来フコイダン多糖およびその利用 |
US20070218076A1 (en) * | 2003-07-28 | 2007-09-20 | Michailovna Shevchenko N | Method of Processing Seaweed |
CN101250232A (zh) * | 2008-03-27 | 2008-08-27 | 钱国英 | 一种羊栖菜活性多糖的提取工艺 |
CN101912408A (zh) * | 2010-06-24 | 2010-12-15 | 首都医科大学 | 褐藻多糖硫酸酯在制备预防和治疗糖尿病血管疾病药物中的应用 |
CN102234336A (zh) * | 2010-04-24 | 2011-11-09 | 中国科学院海洋研究所 | 一种岩藻半乳聚糖硫酸酯及其提取分离纯化方法与应用 |
-
2013
- 2013-06-08 CN CN201310228728.5A patent/CN103288978B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040105523A (ko) * | 2003-06-07 | 2004-12-16 | 박응렬 | 갈조류로 부터 생리활성물질 연속추출 및 기능성 식품제조 |
US20070218076A1 (en) * | 2003-07-28 | 2007-09-20 | Michailovna Shevchenko N | Method of Processing Seaweed |
CN1560086A (zh) * | 2004-03-12 | 2005-01-05 | 中国海洋大学 | 一种高硫酸根含量岩藻聚糖硫酸酯的制备方法 |
JP2006233099A (ja) * | 2005-02-25 | 2006-09-07 | Univ Of Ryukyus | 褐藻類盤状体由来フコイダン多糖およびその利用 |
CN101250232A (zh) * | 2008-03-27 | 2008-08-27 | 钱国英 | 一种羊栖菜活性多糖的提取工艺 |
CN102234336A (zh) * | 2010-04-24 | 2011-11-09 | 中国科学院海洋研究所 | 一种岩藻半乳聚糖硫酸酯及其提取分离纯化方法与应用 |
CN101912408A (zh) * | 2010-06-24 | 2010-12-15 | 首都医科大学 | 褐藻多糖硫酸酯在制备预防和治疗糖尿病血管疾病药物中的应用 |
Non-Patent Citations (3)
Title |
---|
ELLYA SINURAT等: ""FUCOIDAN FROM BROWN SEAWEED AND ITS BIOACTIVITY"", 《SQUALEN》 * |
吴建东等: ""厚叶切氏海带多糖的提取分离及其结构表征"", 《中国海洋大学学报》 * |
李苗苗等: ""多肋藻(Costaria costata)多糖的提取分离及理化性质分析"", 《中国海洋药物杂志》 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103554293A (zh) * | 2013-11-18 | 2014-02-05 | 集美大学 | 一种活性低分子量岩藻聚糖的制备方法及其用途 |
CN103554293B (zh) * | 2013-11-18 | 2016-08-17 | 集美大学 | 一种活性低分子量岩藻聚糖的制备方法及其用途 |
CN104710539A (zh) * | 2013-12-17 | 2015-06-17 | 深圳海王药业有限公司 | 岩藻聚糖硫酸酯及其制备方法 |
CN104710539B (zh) * | 2013-12-17 | 2017-07-07 | 深圳海王医药科技研究院有限公司 | 岩藻聚糖硫酸酯及其制备方法 |
CN104173231A (zh) * | 2014-08-04 | 2014-12-03 | 法国微拉芙生命科学研究院亚洲研发中心有限公司 | 墨角藻提取物的提取方法及其在抗衰老化妆品中的应用 |
CN104586878A (zh) * | 2015-01-14 | 2015-05-06 | 青岛海洋生物医药研究院股份有限公司 | 岩藻聚糖硫酸酯及低分子量岩藻聚糖硫酸酯在制备抗代谢综合症的药物和保健品中的应用 |
CN106749733A (zh) * | 2016-12-21 | 2017-05-31 | 盐城工学院 | 一种泡叶藻硫酸酯化多糖及其制备方法、应用 |
CN106749733B (zh) * | 2016-12-21 | 2020-02-14 | 盐城工学院 | 一种泡叶藻硫酸酯化多糖及其制备方法、应用 |
CN110437288A (zh) * | 2019-09-02 | 2019-11-12 | 中国海洋大学 | 一种新型海参岩藻多糖及其制备方法和应用 |
CN110437288B (zh) * | 2019-09-02 | 2021-06-08 | 中国海洋大学 | 一种海参岩藻多糖及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103288978B (zh) | 2015-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103288978B (zh) | 岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用 | |
CN101301310B (zh) | 褐藻多糖硫酸酯在预防和治疗帕金森病中的用途 | |
CN1985847B (zh) | 低分子量褐藻多糖硫酸酯在制备治疗心脑血管疾病的药物中的用途 | |
CN101347422B (zh) | 丹酚酸a在预防和\或治疗糖尿病及并发症中的应用 | |
CN110812364A (zh) | 半乳寡糖及其衍生物在作为SGLTs抑制剂中的应用 | |
CN104586878A (zh) | 岩藻聚糖硫酸酯及低分子量岩藻聚糖硫酸酯在制备抗代谢综合症的药物和保健品中的应用 | |
CN106220701B (zh) | 三萜化合物及其制备方法与应用 | |
CN101564378B (zh) | 左卡尼汀口服溶液及其制备方法 | |
CN102698271B (zh) | 一种降糖药物组合物及其应用 | |
CN105395563A (zh) | 低聚古罗糖醛酸及其衍生物在制备预防和治疗高脂血症及其并发症的药物和保健品中的应用 | |
CN105769928A (zh) | 丁酸梭状芽孢杆菌在防治或辅助治疗高血糖制剂中的应用 | |
CN101732292B (zh) | 四氢姜黄素的用途 | |
CN103622946A (zh) | 淫羊藿苷元的医药用途 | |
CN101953867B (zh) | 天山雪莲石油醚提取物及其应用制备方法和应用 | |
CN101612142A (zh) | 肌醇衍生物或其盐在制药中的用途 | |
CN103110626B (zh) | 一种药物组合物及其应用 | |
CN101254200B (zh) | 青钱柳苷类化合物在制备治疗糖尿病药物中的用途 | |
CN101422491A (zh) | 可作为α-葡萄糖苷酶抑制剂的桦褐孔菌提取物制备方法 | |
CN104784192B (zh) | 蚌肉寡糖在制备降血糖药物中的应用及其制备方法 | |
CN110227080A (zh) | 甘露葡萄糖醛酸多(寡)糖及其衍生物在制备治疗和/或预防2型糖尿病药物中的应用 | |
CN103110659A (zh) | 海参硫酸多糖在制备抗ii型糖尿病药物或制品中的应用 | |
CN103860578A (zh) | 香菇多糖作为抗抑郁症药物的用途 | |
CN114652740B (zh) | 一种益母草碱、黄精多糖和脱氧野尻霉素药物组合物及其应用 | |
CN103356637B (zh) | 毛壳素在制备预防和治疗心脏病药物中的应用 | |
CN102228500A (zh) | 常春卫矛制剂的生产方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160503 Address after: 264200 No. 20 Yong Jiang Street, Zhang Town, Huancui District, Shandong, Weihai Patentee after: WEIHAI ZHIEN PHARMACEUTICAL Co.,Ltd. Address before: 266003 Shandong province Qingdao City fish Road No. 5 Patentee before: Ocean University of China |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 264200 No. 20 Yong Jiang Street, Zhang Town, Huancui District, Shandong, Weihai Patentee after: Weihai Rensheng Group Co.,Ltd. Address before: 264200 No. 20 Yong Jiang Street, Zhang Town, Huancui District, Shandong, Weihai Patentee before: WEIHAI ZHIEN PHARMACEUTICAL Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160912 Address after: 264200 No. 20 Yong Jiang Street, Zhang Town, Huancui District, Shandong, Weihai Patentee after: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Address before: 264200 No. 20 Yong Jiang Street, Zhang Town, Huancui District, Shandong, Weihai Patentee before: Weihai Rensheng Group Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Fucoidan and its preparation method and application in the preparation of anti diabetes a- Application of glucosidase inhibitors Effective date of registration: 20220526 Granted publication date: 20151028 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006536 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230602 Granted publication date: 20151028 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2022980006536 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Fucan Organosulfate and its preparation method and its application in the preparation of anti diabetes a- Application of Glycosidase Inhibitors Effective date of registration: 20230606 Granted publication date: 20151028 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980042918 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20151028 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980042918 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Fucosan sulfate, its preparation method and application in the preparation of a - glucosidase inhibitor against diabetes Granted publication date: 20151028 Pledgee: Weihai commercial bank Limited by Share Ltd. revitalization branch Pledgor: WEIHAI RENSHENG PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980022070 |